tilsotolimod: Clinical Trials

9 trials of tilsotolimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 5 Phase 1, 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Terminated 1
Phase 23Active not recruiting 1, Completed 1, Recruiting 1
Phase 31Terminated 1

Follow tilsotolimod: new trials by email Literature Review of tilsotolimod trials Research Report on tilsotolimod

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
Ipilimumab, Nivolumab, Tilsotolimod - Advanced Cancer
Phase 1TerminatedGustave Roussy, Cancer Campus, Grand Paris252020-04-102024-10-18
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Tilsotolimod, Saline (0.9% sodium chloride) - Malignant Melanoma
Phase 2RecruitingA.J.M. van den Eertwegh2142020-01-222021-04-15
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer
Phase 1CompletedAbbVie302020-01-222023-02-27
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Tilsotolimod, Nivolumab, Ipilimumab - Solid Tumor
Phase 2Active not recruitingIdera Pharmaceuticals, Inc.302019-10-292022-02-17
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Ipilimumab, Tilsotolimod with Ipilimumab - Metastatic Melanoma
Phase 3TerminatedIdera Pharmaceuticals, Inc.4812018-05-302022-11-08
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
IMO-2125 - Refractory Solid Tumors, Melanoma
Phase 1CompletedIdera Pharmaceuticals, Inc.542017-06-092020-02-11
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
IMO-2125, Ipilimumab - Metastatic Melanoma
Phase 2CompletedIdera Pharmaceuticals, Inc.532015-12-012022-08-03
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
IMO-2125, Saline - Hepatitis C, Treatment Naïve, Genotype 1 Patients
Phase 1CompletedIdera Pharmaceuticals, Inc.632009-09-012019-02-15
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
IMO-2125, Saline placebo - Hepatitis C
Phase 1CompletedIdera Pharmaceuticals, Inc.582007-09-012019-02-15

Conditions studied

Melanoma (4)  ·  Hepatitis C (2)  ·  Carcinoma, Squamous Cell (1)  ·  Diabetes Mellitus, Insulin-Dependent, 12 (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Skin Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Idera Pharmaceuticals, Inc. (6)  ·  A.J.M. van den Eertwegh (1)  ·  AbbVie (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)

Countries

United States (6)  ·  France (4)  ·  Netherlands (3)  ·  Germany (2)  ·  Israel (2)  ·  Spain (2)  ·  Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  Italy (1)  ·  Puerto Rico (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Alice Bexon, MD (1)  ·  Tanja de Gruijl (1)

Results publications

PMID 40048691, PMID 41956545

NIH funding

2018 (1), 2019 (1)